3 Ways to Invest in Ketamine Clinics
January 6th, 2022
App, Exclusive, Psychedelics, Top Story
Researchers believe that psychedelics may revolutionize mental health treatments, but FDA-approved psychedelics remain out of reach—with one exception. Unlike psilocybin or MDMA, ketamine is FDA-approved for anesthesia during medical procedures, opening the door to off-label use as a treatment for depression and other mental illnesses.
With the FDA’s approval of Spravato and a growing body of research supporting ketamine, patients are increasingly turning toward these clinics to solve their unmet medical needs.
Ketamine clinics charge between $450 and $500 per treatment, with each patient needing approximately six treatments. In aggregate, some analysts estimate that the market is already worth north of $16 billion per year, with rapid growth possible over the coming years.
Let’s take a look at three ways that you can invest in ketamine clinics.
Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTC: RVLWF) (FSE:4DO) is one of the most exciting pure-plays in the ketamine clinic space. Since opening its first clinic in 2018, the company has built a network of eight clinics across four states, with two additional clinics to open by the end of the year in Bethesda, MD and a second Knoxville, TN location. In addition, January 1, 2022 will see two newly acquired clinics in Richmond, VA. and Jacksonville, FL, with more than 60,650 sq. ft. of space and clinical capacity for more than 120 treatment rooms. All of Revitalist’s treatments are provided by certified registered nurse anesthetists with ketamine experience and mental health or psychiatric practitioners licensed to administer the drug.
Last quarter, the company reported $1.55 million in revenue and $1.17 million in gross income for the ten months leading up to October 31, 2021. Management believes that its existing 120 treatment rooms could generate upwards of $60 million in annual revenue, while it plans to open 50 clinics in 2022 before reaching 150 clinics by 2025.
The company also plans to launch a telemedicine platform over the coming months. These efforts could significantly expand its addressable market across geographies. And with its 60% acquisition of Revitaland Meta Tech Inc., the platform could expand to include virtual clinics in the metaverse—a rapidly growing innovation spearheaded by Facebook.
Click here to learn more about investing in Revitalist
Field Trip Health
Field Trip Health Ltd. (NASDAQ: FTRP) is the largest ketamine clinic operator with a $150 million market capitalization. In addition to psychedelic drug development, the company operates six clinics and plans to expand to 75 locations by 2024. These clinics provide psychedelic-assisted psychotherapy with the help of ketamine.
The company also provides a digital platform to support patients through their therapeutic journey. The platform offers mood monitoring, mindfulness tools, information, and guided meditations, along with video calls and asynchronous text communication. The goal is to help collect data and improve patient outcomes.
Novamind Inc. (CSE: NM) (OTC: NVMDF) operates a network of six ketamine clinics and clinical research sites in Utah. In 2022, the company plans to add new clinics in Utah and expand into Arizona for a total of ten clinics. These will include a center for immersive psychedelic experiences in Park City, Utah, a world-class travel and wellness destination.
In addition to ketamine therapies, the company operates a full-service psychedelic contract research organization (CRO) with three clinical research sites and a DEA Schedule 1 license for psilocybin research. These facilities could help it play a role in the study and eventual approval of psilocybin, MDMA, and other psychedelic therapies.
Ketamine clinics are quickly becoming a multi-billion dollar business driven by rapidly growing demand. Investors interested in the space have several options, including pure-plays like Revitalist Lifestyle & Wellness Ltd. (CSE: CALM) (OTC: RVLWF).
For more information, visit the company’s website or download their investor presentation.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.